On 29 January 2019 DCprime has received approval from the Norwegian Medicines Agency NoMa for the ADVANCE-II / DCOne-002 clinical study entitled ‘An international, multicenter, open-label study to evaluate the efficacy and safety of two different vaccination regimens of immunotherapy with allogeneic dendritic cells, DCP-001, in patients with acute myeloid leukaemia that are in remission with persistent MRD’. This multi-center study can now expand its treatment area, next to The Netherlands and Germany, also to Norway. The fist clinical site to be activated will be led by Prof. Dr. Bjorn Gjertsen from Department of Clinical Science of the University of Bergen.